Thank you, Scott.
on This Cushing we the study syndrome. morning III an endogenous update treatment of RECORLEV Phase of provided LOGICS for the
intended is controlled subjects RECORLEV. blind, of randomize double the As and of to subjects upon placebo LOGICS therapeutic subjects with assess XX compared a with to XX to of withdrawal treatment upon RECORLEV. loss to a the that placebo, is primary RECORLEV a proportion is a proportion enrollment The with reminder, therapeutic efficacy targeting response of continuing withdrawing with approximately endpoint safety response the of loss study for
have to designed, placebo we this study the and in response conservatively proportions reflecting difference entrance. XX% lead As between a this will active project groups we that significant loss statistically of a minimum the powered
we a that from of results Although first will of most project or of XXXX. now completing study of second progress report by delay the recent we topline projection the we made in topline third quarter quarter for end results the XXXX have LOGICS, the our towards
some for the study same investigators our LOGICS projection the many to criteria quarters. sites like We receive enrollment moments the a earlier would take the Europe. and prior as and nearly to SONICS topline and States two it take few on provide around III had in Phase entry identical as study, reasons context the will for to employed I the time projections United of for why LOGICS, the our naturally completed explain spans largely results based delay,
level provide barriers enrollment. site that was experience as Furthermore, from and impact support patient we enrollment investigator services to to to much SONICS concierge such remove to how LOGICS the learned anticipated positively optimal support
in However, as differences of to time, we to be terms the have SONICS so, design remain of and about months appreciate Logics we differences more come how to specific. LOGICS intensity and LOGICS or on procedural particularly translating over fundamental and the potential have in and past learned sign with between of into nine participants willingness to
should now label willing immediate is that even it’s did Cushing SONICS which of participants LOGICS otherwise prospect syndrome bear believe exist comparison that of cannot open symptoms in therapy We RECORLEV. not use some the in available, placebo a a though rescue
twice time caused are visits there enrollment. factors in Checking as have in LOGICS to and SONICS also revisit of taking procedures to together, be many complete on LOGICS, as appears time. of intensity our the for this And enrollment per speed. As to in these us unit toll
phases, walk variability through subject of each The of the results third provides the plus we screening, to did me LOGICS is time window complete for those. are topline time that a I LOGICS of year. it design quarters on three reporting takes for of want and allowing next let phase. second four therapeutic comment comprised spans in to large phases, that fairly the the you
four weeks designed procedures On about Screening are to six the to it determine trial. average, screening. complete takes eligibility to for
therapeutic titration maintenance open is an phase label The and first phase.
RECORLEV or minimum for weeks to achieve phase. the urinary progressing and UFC of must receive normalization During mean increasing doses stable to free this next phase, a cortisol, dose before maintain of patients four needed a as of
with must for time exceptional each on phase minimum XX this routinely, that additional basis. up XX allowed spend for an approximately to allow weeks completion and in The we time is patient weeks
So in titration weeks and maintenance at enrolled is primary there are to a endpoint randomize five Participants the the phase determined. into dose withdrawal therapeutic over The which then between study the their phase. longest shortest in is range extending the durations phase.
phase, therapeutic equivalent an or which number receive active of at drug the dose, In placebo assigned to established randomly blinded either patients randomize matching is study tablets. drug, withdrawal are their
to label restoration. determine continuing phase control symptoms the therapy including have final being USC be patient of known well control to or documented are loss XX patient respond every markers, is immediately days RECORLEV of if with cortisol directly who this open into and moved phase as approximately Biochemical the rescued be cortisol Patients study and assessed during is can lost. to
The to considered completion the early is be primary with definition of need the purposes outcome loss protocol assessing as by study response. endpoint for your rescue for assessed
phase. rescue So can occur two this an about early after weeks into
maintain and weeks patients In eight XX up therapy sooner who and withdrawal, randomization. half of which weeks visits response and the contrast, all require do therapy the who approximately occurs their rescue not no date randomize to complete following to than
the patient a cycle determines will or Therefore, two a early variability rescue weeks about withdrawal whether patient phase. randomize the requires or It complete represents of time that seven about therapy of months. duration require to not time
Taking accounting or randomize maintenance are that weeks and receipt phases about the reporting to variability timing both is of withdrawal XX results months, specified topline to for we in complete required time protocol together the and range the titration today. three the approximately the
of results able next been the completed maintenance more topline the participant randomized has once phase We provide a should last be estimate has year. and precise the titration of to timing
results six after relates it to can are months the topline submit an approximately LOGICS NDA we NDA As reported. submission, believe we
a XXX expect if XX which previously, the we accepted review is of believe submission, time cycle review of new PDUFA a review, we for standard stated NDA NDA that via of is As time months for date from cycle pathway. (b)(X), the can active our the substance
and a that two would we recommended of monitoring RECORLEV meeting of board to end therapy. data held like benefits the The on safety risks annual on I and based by their LOGICS study highlight October, for updates the at as and of first assessment the planned. continues routine other DSMB
Diabetes phase SONICS were Second study & in end of The Endocrinology. including results Phase September, the the published maintenance in pivotal to of Lancet, online the comprehensive RECORLEV III
We are currently working we that to expect in SONICS publications on additional published be XXXX.
call quarter we CFO from turn open Lutz, I the will to highlights the third Rob questions. that, our financial over will call review who Rob? to With the before
